Login to Your Account



Mast Therapeutic's phase III sickle cell trial EPIC misses endpoint

By Michael Fitzhugh
Staff Writer

Wednesday, September 21, 2016

Mast Therapeutics Inc. expects to quit development of its lead candidate, vepoloxamer, after it failed to significantly outperform a placebo in shortening the duration of VOC in the phase III trial EPIC.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription